Talk:Ofranergene obadenovec

Medicine: Hematology-oncology Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.
	This article is supported by the Hematology-oncology task force.

Pharmacology

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
???	This article has not yet received a rating on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ofranergene obadenovec.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Developer edit

Latest comment: 6 years ago5 comments3 people in discussion

This source states clearly that the drug is being developed by "Dana-Farber Cancer Institute; Massachusetts General Hospital; VBL Therapeutics". Why is only the last mentioned in the article? You should mention all or none, I think. Justlettersandnumbers (talk) 21:42, 23 February 2017 (UTC)Reply

The drug itself was developed by VBL. Dana-Farber (which is associated with Mass Gen) is being used to host clinical trials and further testing of the drug. Natureium (talk) 15:26, 24 February 2017 (UTC)Reply

But that isn't what the source says, is it? Justlettersandnumbers (talk) 15:44, 24 February 2017 (UTC)Reply

From the first sentence: "VBL Therapeutics (also known as Vascular Biogenics) is developing ofranergene obadenovec, an intravenously administered dual-action, anti-angiogenic and vascular disrupting agent (VDA), for the treatment of solid tumours." and the table further down the page: "VBL Therapeutics, Owner, Israel; Dana-Farber Cancer Institute, Collaborator, USA; Massachusetts General Hospital, Collaborator, USA" Natureium (talk) 15:50, 24 February 2017 (UTC)Reply

yep, the drug is owned by VBL and is being developed by them at various sites. adis lists clinical trial sites. Dana Farber is one of them. Jytdog (talk) 19:56, 29 August 2017 (UTC)Reply

Add topic